CCie, it would certainly feel “sudden” to most of Merck’s shareholders if they come out with a PR on the data from the Combo trial with us shortly after our TLD release, which we believe is imminent. At least suddenly we’ll have a BP pushing the FDA to approve DCVaxL for their benefit, as well as ours.